View Older Stories View More Recent Stories

Jun 4, 2018 09:00AM Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting
Jun 4, 2018 09:00AM Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors
May 30, 2018 04:01PM Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13
May 30, 2018 05:53AM Gilead Sciences (GILD) Reports Chinese Approval of Epclusa (Sofosbuvir/Velpatasvir)
May 30, 2018 01:00AM China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection
May 23, 2018 04:01PM Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6
May 15, 2018 11:05AM Gilead Sciences (GILD) Says FDA Approves Expanded Indication for Truvada for Reducing the Risk of Acquiring HIV-1 in Adolescents
May 15, 2018 10:59AM U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
May 15, 2018 08:30AM Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
May 9, 2018 04:48PM Gilead Sciences (GILD) Appoints Harish M. Manwani to Board
May 9, 2018 04:30PM Harish Manwani Joins Gilead Sciences’ Board of Directors
May 8, 2018 09:00AM Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16
May 1, 2018 04:02PM Gilead Sciences Announces Second Quarter 2018 Dividend
Apr 30, 2018 04:05PM Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
Apr 27, 2018 06:37AM Gilead Sciences (GILD) Reports European CHMP Adopts Positive Opinion for Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
Apr 27, 2018 06:36AM European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
Apr 17, 2018 05:00PM Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018
Apr 13, 2018 10:16AM Gilead (GILD) Presents Data on Multiple Investigational Regimens for Treatment of NASH and Advanced Fibrosis at The International Liver Congress
Apr 13, 2018 10:15AM Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018
Mar 12, 2018 09:10AM Gilead (GILD) Says Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Mar 12, 2018 09:10AM Gilead (GILD) Says Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Mar 12, 2018 09:00AM Gilead Sciences’ Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Mar 5, 2018 04:01PM Gilead Sciences (GILD) Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy From Boosted Protease Inhibitor-Based Regimen
Mar 5, 2018 04:00PM Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted El
Mar 5, 2018 12:08PM Gilead (GILD) Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy from Regimen Containing Abacavir, Dolutegravir and Lamivudine
Mar 5, 2018 12:07PM Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lami
Mar 5, 2018 05:48AM Gilead Sciences (GILD) Reports Preclinical Data on Study Evaluating Combination of GS-9620 and PGT121
Mar 4, 2018 04:19PM Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed
Feb 22, 2018 05:04PM Gilead Sciences (GILD) Says James Meyers, EVP, Commercial Operations, Will Retire
Feb 22, 2018 05:00PM Gilead Sciences Announces Senior Management Change
Feb 8, 2018 04:01PM Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21
Feb 7, 2018 02:24PM Gilead Sciences (GILD) Announces FDA Approval for Biktarvy for Treatment of HIV-1 Infection
Feb 7, 2018 02:22PM U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Feb 6, 2018 04:02PM Gilead Sciences Announces 10 Percent Increase in First Quarter 2018 Dividend
Feb 1, 2018 04:05PM Jacqueline K. Barton, Ph.D., Joins Gilead Sciences’ Board of Directors
Jan 23, 2018 04:01PM Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018
Jan 18, 2018 08:32AM Gilead's (GILD) Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta and Pfizer's (PFE) Utomilumab in Large B-Cell Lymphoma
Jan 18, 2018 08:30AM Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
Dec 21, 2017 04:01PM Gilead Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8
Dec 14, 2017 04:31PM Gilead Sciences (GILD) Says John C. Martin to Transition From Executive Chairman to Chairman
Dec 14, 2017 04:30PM Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors
Dec 12, 2017 05:56AM Gilead Sciences (GILD) Company, Kite, Reports Data From ZUMA-3 Study of KTE-C19
Dec 11, 2017 07:30PM Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Dec 11, 2017 06:08AM Gilead Sciences' (GILD) Kite LT Pivotal ZUMA-1 Study of Yescarta Shows 42% of Patients Remained in Response, Including 40% in Complete Remission
Dec 10, 2017 10:30AM Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
Dec 7, 2017 05:01PM Gilead Sciences (GILD) and Kite to Acquire Cell Design Labs for up to $567M
Dec 7, 2017 05:00PM Gilead Sciences and Kite to Acquire Cell Design Labs
Dec 4, 2017 06:30AM Gilead Announces 10-Year, $100 Million Commitment to Address the HIV/AIDS Epidemic in the Southern United States
Nov 22, 2017 09:00AM Gilead Sciences to Present at the Nasdaq 37th Investor Program on Wednesday, December 6
Oct 26, 2017 04:02PM Gilead Sciences Announces Fourth Quarter 2017 Dividend
View More Recent Stories View Older Stories